Brandee L Branche1, Lauren E Howard2, Daniel M Moreira3, Claus Roehrborn4, Ramiro Castro-Santamaria5, Gerald L Andriole6, Martin L Hopp7, Stephen J Freedland8. 1. Surgery Section, Durham Veterans Affairs Medical Center, Durham, North Carolina. 2. Surgery Section, Durham Veterans Affairs Medical Center, Durham, North Carolina; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina. 3. University of Illinois at Chicago, Chicago, Illinois. 4. University of Texas Southwestern Medical Center, Dallas, Texas. 5. Metabolic Pathways and Cardiovascular R&D Unit, GlaxoSmithKline, Inc., King of Prussia, Pennsylvania. 6. Washington University School of Medicine in St. Louis, St. Louis, Missouri. 7. Cedars-Sinai Medical Center, Los Angeles, California. 8. Surgery Section, Durham Veterans Affairs Medical Center, Durham, North Carolina; Cedars-Sinai Medical Center, Los Angeles, California. Electronic address: stephen.freedland@cshs.org.
Abstract
PURPOSE: Although lower urinary tract symptoms and sleep problems often develop together, to our knowledge it is unknown whether sleep disturbances are linked to lower urinary tract symptoms development and progression. As measured by the 6-item MOS-Sleep (Medical Outcomes Study Sleep Scale) survey we examined the relationship between sleep problems, and the development and progression of lower urinary tract symptoms in the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) study. MATERIALS AND METHODS: REDUCE was a randomized trial testing prostate cancer chemoprevention with dutasteride in men with prostate specific antigen 2.5 to 10 ng/ml and a negative biopsy. At baseline men completed MOS-Sleep and a scaled average was used to calculate the sleep score. Men were followed for 4 years and I-PSS (International Prostate Symptom Score) was completed at baseline and every 6 months. Asymptomatic men had I-PSS less than 8 while symptomatic men had I-PSS 8 or greater. In the placebo arm of 2,588 men not receivingα-blockers or 5α-reductase inhibitors at baseline we tested the association between sleep problems and lower urinary tract symptom development and progression using Cox models. RESULTS: During followup lower urinary tract symptoms developed in 209 of 1,452 asymptomatic men (14%) and 580 of 1,136 (51%) with lower urinary tract symptoms demonstrated progression. On multivariable analysis higher sleep scores were suggestively associated with increased lower urinary tract symptoms in asymptomatic men (quartile 4 vs 1 HR 1.41, 95% CI 0.92-2.17, p = 0.12) and with lower urinary tract symptom progression in symptomatic men (per 10 points of sleep score HR 1.06, 95% CI 1.01-1.12, p = 0.029). CONCLUSIONS: Among men with lower urinary tract symptoms worse sleep scores were associated with the progression of lower urinary tract symptoms and among asymptomatic men worse sleep scores were suggestively associated with the development of lower urinary tract symptoms. If confirmed, these data suggest that sleep problems may precede such symptoms. Whether treating sleep problems would improve lower urinary tract symptoms requires further testing.
RCT Entities:
PURPOSE: Although lower urinary tract symptoms and sleep problems often develop together, to our knowledge it is unknown whether sleep disturbances are linked to lower urinary tract symptoms development and progression. As measured by the 6-item MOS-Sleep (Medical Outcomes Study Sleep Scale) survey we examined the relationship between sleep problems, and the development and progression of lower urinary tract symptoms in the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) study. MATERIALS AND METHODS: REDUCE was a randomized trial testing prostate cancer chemoprevention with dutasteride in men with prostate specific antigen 2.5 to 10 ng/ml and a negative biopsy. At baseline men completed MOS-Sleep and a scaled average was used to calculate the sleep score. Men were followed for 4 years and I-PSS (International Prostate Symptom Score) was completed at baseline and every 6 months. Asymptomatic men had I-PSS less than 8 while symptomatic men had I-PSS 8 or greater. In the placebo arm of 2,588 men not receiving α-blockers or 5α-reductase inhibitors at baseline we tested the association between sleep problems and lower urinary tract symptom development and progression using Cox models. RESULTS: During followup lower urinary tract symptoms developed in 209 of 1,452 asymptomatic men (14%) and 580 of 1,136 (51%) with lower urinary tract symptoms demonstrated progression. On multivariable analysis higher sleep scores were suggestively associated with increased lower urinary tract symptoms in asymptomatic men (quartile 4 vs 1 HR 1.41, 95% CI 0.92-2.17, p = 0.12) and with lower urinary tract symptom progression in symptomatic men (per 10 points of sleep score HR 1.06, 95% CI 1.01-1.12, p = 0.029). CONCLUSIONS: Among men with lower urinary tract symptoms worse sleep scores were associated with the progression of lower urinary tract symptoms and among asymptomatic men worse sleep scores were suggestively associated with the development of lower urinary tract symptoms. If confirmed, these data suggest that sleep problems may precede such symptoms. Whether treating sleep problems would improve lower urinary tract symptoms requires further testing.
Authors: Scott R Bauer; Rebecca Scherzer; Anne M Suskind; Peggy Cawthon; Kristine E Ensrud; William A Ricke; Kenneth Covinsky; Lynn M Marshall Journal: J Am Geriatr Soc Date: 2020-08-21 Impact factor: 5.562
Authors: Mikolaj Przydacz; Michal Skalski; Jerzy Sobanski; Marcin Chlosta; Karol Raczynski; Katarzyna Klasa; Dominika Dudek; Piotr Chlosta Journal: Medicina (Kaunas) Date: 2021-04-19 Impact factor: 2.430
Authors: Mikolaj Przydacz; Tomasz Golabek; Przemyslaw Dudek; Michal Skalski; Jerzy Sobanski; Katarzyna Klasa; Katarzyna Gronostaj; Dominika Dudek; Piotr Chlosta Journal: Int Neurourol J Date: 2021-01-19 Impact factor: 2.835